Answers are grounded in this paper and cite their sources.
Evaluate the benefit-risk assessment of atogepant and calcitonin gene– related peptide (CGRP) monoclonal antibodies (mAbs) vs placebo based on number needed to treat (NNT) and number needed to harm (NNH) in a blended episodic and chronic migraine population (EM+CM).
No takes yet. Share an insight, caveat, or question.
Sacco et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: